Cargando…

Acute cholangitis following mRNA COVID-19 vaccine booster in a patient receiving an anti-amyloid antibody for Alzheimer’s disease: A case report

A 77-year-old woman had 2 weeks of fever and flu-like symptoms starting several hours after receiving an mRNA booster for SARS-CoV-2 and the influenza vaccine, in separate shots. Laboratory tests showed cholangitis. Medical history included APOE-ε4 carrier genotype, mild Alzheimer’s disease, partici...

Descripción completa

Detalles Bibliográficos
Autores principales:	Restifo, Linda L, Erickson, Robert P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467250/ https://www.ncbi.nlm.nih.gov/pubmed/37654545 http://dx.doi.org/10.1177/2050313X231194507

Ejemplares similares

Imaging of Myocarditis Following mRNA COVID-19 Booster Vaccination
por: Sanchez Tijmes, Felipe, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
por: Goh, Yun Shan, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
Publicado: (2023)

Immune Thrombocytopenia Following Booster Dose of the Moderna mRNA-1273 Vaccine
por: Breetz, Katherine A, et al.
Publicado: (2022)

Comparative effects of mRNA vaccine booster and natural Omicron infection on the neutralizing antibody response
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Evaluation of Antibody Response and Adverse Effects following Heterologous COVID-19 Vaccine Booster with mRNA Vaccine among Healthcare Workers in Indonesia
por: Soegiarto, Gatot, et al.
Publicado: (2023)

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination
por: Parés-Badell, Oleguer, et al.
Publicado: (2022)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

Acute panuveitis after COVID-19 mRNA booster vaccination following cataract surgery
por: Kung, Timothy-Paul H., et al.
Publicado: (2022)

Anti-amyloid: An antibody to cure Alzheimer’s or an attitude
por: Osborne, Olivia M., et al.
Publicado: (2023)

Immunogenicity against the Omicron Variant after mRNA-Based COVID-19 Booster Vaccination in Medical Students Who Received Two Primary Doses of the mRNA-1273 Vaccine
por: Chung, Hyemin, et al.
Publicado: (2022)

mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines
por: Zhang, Biyan, et al.
Publicado: (2022)

Acute Pericarditis Post mRNA-1273 COVID Vaccine Booster
por: Singh, Arminder, et al.
Publicado: (2022)

Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years
por: Durier, Christine, et al.
Publicado: (2022)

Vaccine-induced immune thrombocytopenia and thrombosis after mRNA-1273 booster vaccination
por: Langerak, T., et al.
Publicado: (2022)

Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
por: Stellini, Roberto, et al.
Publicado: (2022)

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster
por: Lusvarghi, Sabrina, et al.
Publicado: (2021)

Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2
por: Özbay Kurt, Feyza Gül, et al.
Publicado: (2022)

Fourth-dose boosters with COVID-19 mRNA vaccines well tolerated
Publicado: (2022)

Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US
por: Hause, Anne M., et al.
Publicado: (2022)

Memory B cell development elicited by mRNA booster vaccinations in the elderly
por: Wang, Zijun, et al.
Publicado: (2023)

Durability of immune responses to mRNA booster vaccination against COVID-19
por: Arunachalam, Prabhu S., et al.
Publicado: (2023)

Anaphylaxis induced by mRNA COVID-19 vaccines: follow-up and booster dose after previous desensitization
por: AlOtaibi, Ibtihal, et al.
Publicado: (2023)

Delayed Onset of Symptomatic Dermatographism following COVID-19 mRNA Booster
por: Co, Margaret
Publicado: (2023)

Severe Thrombocytopenia, Thrombosis and Anti-PF4 Antibody after Pfizer-BioNTech COVID-19 mRNA Vaccine Booster—Is It Vaccine-Induced Immune Thrombotic Thrombocytopenia?
por: Ling, Victor W. T., et al.
Publicado: (2022)

A case of anti-MOG antibody-positive ADEM following COVID-19 mRNA vaccination
por: Miyamoto, Katsuichi, et al.
Publicado: (2022)

Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study
por: Quiroga, Borja, et al.
Publicado: (2022)

Neutralizing antibodies against the SARS-CoV-2 Omicron variant following two CoronaVac vaccinations and a Pfizer/BioNTech mRNA vaccine booster
por: da Silva, Almir Ribeiro, et al.
Publicado: (2022)

Antibody response after a booster dose of BNT162B2mRNA and inactivated COVID-19 vaccine
por: Yigit, Metin, et al.
Publicado: (2022)

Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan
por: Sanada, Takahiro, et al.
Publicado: (2023)

Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant
por: Tay, Matthew Zirui, et al.
Publicado: (2023)

mRNA-based COVID-19 Vaccines Booster Dose: Benefits, Risks, and Coverage
por: Nashwan, Abdulqadir J., et al.
Publicado: (2022)

Abstract #1403045: Thyroiditis Post COVID-19 mRNA Booster Dose Vaccination
por: Seow, Cherng Jye
Publicado: (2023)

1612P Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy
por: Guven, D.C.C., et al.
Publicado: (2022)

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine
por: Tangsathapornpong, Auchara, et al.
Publicado: (2023)

No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination
por: Lu-Culligan, Alice, et al.
Publicado: (2022)

Loss of anti‐spike antibodies following mRNA vaccination for COVID‐19 among patients with multiple myeloma
por: Stampfer, Samuel D., et al.
Publicado: (2023)

Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters
por: Lasrado, Ninaad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jk6i6iv27l86pu9pjq5im45mni